| Property | Value |
|---|
|
?:abstract
|
-
Combined immune checkpoint inhibitor with platinum-based doublet chemotherapy brought about significant improvement in overall survival as the first line treatment in metastatic and recurrent head and neck cancer patients However, in elderly patients with relatively poor performance status, these regimens might not be well tolerated Therefore, we evaluated the safety and effect of combined immunotherapy and single agent chemotherapy in an elderly patient with recurrent head and neck squamous cell carcinoma A 78-year-old male patients with a repeatedly recurrent gingival squamous cell carcinoma was admitted in our institute Previously this patient underwent two consecutive surgical resections of recurrent tumors before the second rapid recurrence that resulted in extended tumor mass and lymph node metastasis As the patient was in a relatively poor performance status (performance status =2), immunotherapy with PD-1 antibody (Toripalimab) combined with single agent chemotherapy (two cycle with albumin-bound paclitaxel and then six cycles with gemcitabine) was administrated, which led to clinical complete response after 8 cycles of treatment The patient continued 4 cycles of maintenance immunotherapy with Toripalimab until the outbreak of the coronavirus disease 2019 The treatment was well tolerated and the patient remained free from disease until the last follow up by June 2020, 16 months after the initiation of treatment The success in this case indicated that the combination of anti-PD-1 antibody and single chemotherapy agent may also be effective as well as safe in elderly patients with recurrent head and neck squamous cell carcinoma
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Complete and enduring response in an elderly patient with repeated recurrent gingival squamous cell carcinoma treated by combined toripalimab and single agent chemotherapy: a case report
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}